問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Neurology

National Taiwan University Hospital

Division of Neurology

更新時間：2023-09-19

黃錦章Huang, Chin-Chang
  • Principal Investigator
  • Clinical Trial Experience (year) 21 years 3 個月

  • cch0537@cgmh.org.tw

  • lydia1022@cgmh.org.tw

Recruiting Trial

19Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

黃錦章

List

64Cases

2021-12-01 - 2024-07-29

Phase II

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Generalized Myasthenia Gravis

  • Condition/Disease

    Generalized Myasthenia Gravis Myasthenia Gravis

  • Test Drug

    ALXN2050

Participate Sites
3Sites

Recruiting3Sites

2021-06-01 - 2026-12-31

Phase II

A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Oral EX039 as Add-on to Acetylcholine Esterase Inhibitors in Subjects with Mild Alzheimer’s Disease

  • Condition/Disease

    Mild Alzheimer Disease

  • Test Drug

    EX039

Participate Sites
4Sites

Recruiting4Sites

2020-08-01 - 2022-07-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2017-08-01 - 2025-07-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2019-08-01 - 2021-07-31

Phase II

Alzheimer's Disease: Clinical Investigation and Neuroimage Studies Including 18F-PM-PBB3 and 18F-florbetapir (AV-45) PET Examination

  • Condition/Disease

    investigate the deposition patterns of tau protein with 18F-PM-PBB3 and amyloid protein with 18F-flobetapir in patients with amnestic mild cognitive impairment due to AD

  • Test Drug

    18F-AV-45 for Injection, and 18F-PM-PBB3 for Injection

Participate Sites
1Sites

Recruiting1Sites

2018-09-21 - 2028-11-30

Others

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2014-08-01 - 2017-07-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2015-08-01 - 2016-07-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

林昆儒
Linkou Chang Gung Medical Foundation

Division of Nuclear Medicine

2015-08-01 - 2018-07-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

黃錦章
Linkou Chang Gung Medical Foundation

Division of Neurology

2017-08-01 - 2020-07-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Suspended1Sites

林昆儒
Linkou Chang Gung Medical Foundation

Division of Nuclear Medicine

1 2 3 4 5 6 7
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB